Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Author(s): Voudrie Mark A, Alexander Bridget, Allen D Brett
Issue: May/Jun 2011 - Volume 15, Number 3
View All Articles in Issue
Page(s): 255-258
Download in electronic PDF format for $75
Abstract: Verapamil hydrochloride is widely prescribed to treat multiple cardiovascular diseases. There are a number of generic manufacturers of verapamil tablets and injectables. The need for other administration options for patients who cannot take tablets has led compounding pharmacies to seek other alternatives, namely, oral solutions and suspensions. The stability of these compounded verapamil oral liquid preparations is a concern to anyone making them. The objective of this study was to determine the stability of verapamil hydrochloride in SyrSpend SF in comparison to stability of verapamil hydrochloride in Ora-Sweet SF:Ora-Plus (1:1). The two samples were compounded in 50-mL batches and stored in amber 60-mL plastic prescription bottles at United States Pharmacopeia refrigerated conditions. Five replicates at each pre-defined time point were assayed by a stability-indicating high performance liquid chromatographic method with an end date of 60 days. No degradation peaks were seen in the chromatograms for either preparation at any time point and the recovery of verapamil hydrochloride was within 90% to 110% of the initial concentration for all replicates. Verapamil hydrochloride is stable in amber plastic prescription bottles for 60 days when refrigerated for both SyrSpend SF and Ora-Sweet SF:Ora-Plus (1:1).
Related Keywords:
verapamil hydrochloride, calcium channel blocker, oral suspensions, syrups, suspending vehicles, stability
Related Categories:
EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Voudrie Mark A, Alexander Bridget, Allen D Brett
|
May/Jun 2011
Pg. 255-258
|
Oral Liquid Vehicles, Featured Excipient:
Allen Loyd V Jr
|
Jan/Feb 2001
Pg. 65-67
|
Stability of Prednisone in Oral Mix Suspending Vehicle
Friciu Mihaela, Plourde Kevin, Leclair Grégoire, Danapoulos Panagiota, Savji Taslim
|
Jul/Aug 2015
Pg. 337-339
|
Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations
Visser J Carolina, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J
|
May/Jun 2018
Pg. 247-251
|
Verapamil Hydrochloride 50 mg/mL in Ora-Plus:Ora-Sweet (1:1)
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 413
|
Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution)
Voudrie Mark A II, Allen D Brett
|
Jan/Feb 2010
Pg. 82-85
|
Chemical Stability of Hydrocortisone in Humco Simple Syrup and Ora-Sweet Vehicle
Gupta Vishnu D
|
Jan/Feb 2010
Pg. 76-77
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul
|
Sep/Oct 2015
Pg. 420-427
|
Verapamil Hydrochloride 2.5-mg/mL Injection
Allen Loyd V Jr
|
Mar/Apr 2013
Pg. 153
|
Verapmail Hydrochloride 50 mg/mL in SyrSpend SF
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 494
|
Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
|
May/Jun 2020
Pg. 252-262
|
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
|
Mar/Apr 2016
Pg. 167-174
|
Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions
Polonini Hudson C, Loures Sharlene, de Araujo Edson Peter, Brandão Marcos Antônio F, Ferreira Anderson O
|
Sep/Oct 2016
Pg. 426-434
|
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition
Bourget Philippe, Amin Alexandre, Vidal Fabrice, Pieyre Manon, Dosso El Ourmar, Beauvais Raphaelle, Loeuillet Richard
|
Sep/Oct 2014
Pg. 427-431
|
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S, Thyangarajapuram N
|
Sep/Oct 2003
Pg. 389-393
|
Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 513-515
|
Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 493
|
Oral Liquid Suspending Vehicle
Allen Loyd V Jr
|
Mar/Apr 2003
Pg. 134
|
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
|
Jul/Aug 2020
Pg. 327-336
|
Return to Top |